NasdaqGS:CAIBiotechs
Caris Life Sciences (CAI) Turns Q4 Profit After US$517 Million Quarterly Loss Testing Bullish Thesis
Caris Life Sciences (CAI) closed FY 2025 with Q4 revenue of US$292.9 million and basic EPS of US$0.29, alongside trailing 12 month revenue of US$812.0 million and a trailing basic EPS loss of US$3.22, set against a 97% year over year revenue increase and expectations for earnings to grow about 70.5% per year with profitability projected within three years. Over recent periods, the company has seen quarterly revenue move from US$101.6 million in Q3 2024 to US$129.9 million in Q4 2024, then to...